Psoriasis. Immunopathology and immunomodulation.
Biologics in development for the treatment of moderate to severe plaque-type psoriasis are discussed in this article. Immunomodulators used as therapeutic, pathogenic probes will continue to identify targets that play primary roles in the pathogenesis of psoriasis.
Gottlieb
A B
AB
Clinical Research Center, University of Medicine and Dentistry New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. gottliab@umdnj.edu
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016207:Cytokines / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology*; D012867:Skin / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D016207:Cytokines; D007166:Immunosuppressive Agents